• 03/14/2025, Sophia Antipolis, France

    Median Technologies meets the eligibility conditions for the PEA-PME scheme

    Median Technologies confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria.
    Read more Download 20250314_PR_PEAPMEScheme_EN.pdf
  • 03/07/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250307_PR_shares_votingrights_Feb2025.pdf
  • 03/03/2025, Sophia Antipolis, France

    Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025

    The documents to be communicated within the context of the Shareholders’ General Meeting may be consulted and downloaded on Median Technologies’ website under the “Shareholder Meetings”  section.
    Read more Download 20250303_PR_EGM_March202025_EN-1.pdf
  • 02/26/2025, Sophia Antipolis, France

    Median Technologies to present at TD Cowen’s 45th Annual Health Care Conference

    Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm ET (9:10 pm CET).
    Read more Download 20250226_PR_Cowen2025_EN_final.pdf
  • 02/24/2025, Sophia Antipolis, France

    Median Technologies to showcase its artificial intelligence Software as a Medical Device for lung cancer screening, eyonis™ LCS, at the European Congress of Radiology

    Median Technologies today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2.
    Read more Download 20250224_PR_ECR2025_EN_final.pdf
  • 02/11/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250211_PR_shares_votingrights_jan2025.pdf
  • 02/05/2025, Sophia Antipolis, France

    Median Technologies gives update on drawdowns of the Iris equity line

    Press release – For immediate release – 5:45 pm CET Median Technologies gives update on drawdowns of the Iris equity line Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of […]
    Read more Download 20250205_PR_IRISstatus_EN-1.pdf
  • 02/03/2025, Sophia Antipolis, France

    eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions

    Top-line data from RELIVE shows that eyonis™ LCS together with radiologist achieved statistically significant improvement over radiologist alone (p=0.027). RELIVE is the second of two pivotal studies required for marketing authorization in U.S. and Europe.
    Read more Download 20250203_PR_RELIVE_topline_EN_Final-2.pdf
  • 01/31/2025, Sophia-Antipolis, France

    Median Technologies reports 2024 key financial indicators and 2025 outlook

    Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.
    Read more Download 20250131_PR_2024keyfigures_EN.pdf
  • 01/24/2025, Sophia Antipolis, France

    Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU

    Repayment of 2020 EIB loan to be rescheduled to October 2025 from April, new €37.5 million 2025 EIB loan under appraisal, final authorization stage and new up to €10 million equity line completed with IRIS to enable 2025 EIB loan
    Read more Download 20250124_PR_Refinancing_final_EN.pdf
    • 1 … 40